Arcus And Gilead Make GI Cancers The Focus Of Their TIGIT Hopes
Gilead ups its investment in its TIGIT partner, as the firms pivot to a less crowded market opportunity in upper GI cancers.
Gilead ups its investment in its TIGIT partner, as the firms pivot to a less crowded market opportunity in upper GI cancers.